Recent news on Increlex

Tercica Reports Increlex Receives CHMP Positive Opinion for the ...  -  25 May 2007
Genetic Engineering News (press release),..."Our collaboration with Ipsen provides us with a very strong partner to commercialize Increlex(R) in the European Union, and represents an important step in

Tercica "neutral"  -  25 May 2007
newratings.comAlthough Tercica has not disclosed any ongoing trials for Increlex, the company is expected to resolve the issue going forward by either submitting for an

In Brief  -  Apr 3, 2007
Nature.com (subscription),Tercica can continue to market Increlex (recombinant IGF-1), which it in-licensed from Genentech, in the US and EU. Insmed, for its part, agreed to take its

Ipsen s Full Year 2006 Results (10º)  -  Mar 18, 2007
InfoBolsa,In January 2007, Tercica began shipments of Increlex(TM) to specialty pharmacy distributors and recorded sales totalling $D0.7 million for the fourth

Tercica Reports Fourth Quarter and Year-End 2006 Financial Results  -  Mar 9, 2007
PharmaLive.com (press release),As of February 28, 2007, 109 patients of the targeted 136 patients (80%) had enrolled in MS301, which is the study evaluating the use of Increlex(TM) in

IGF-1 Case Settled At Last; Favors Tercica Over Insmed  -  Mar 7, 2007
BioWorld Online,If the physician decides they're going to transition to Increlex, we have offered to give them free drugs while we are working on reimbursement."

A Second Look: Tercica Inc.  -  Mar 8, 2007
Houston Chronicle,Now Tercica must look to Increlex, also a growth hormone deficiency treatment, as the next driver for its shares. "The current market opportunity _ the

Children's growth-failure drug lawsuit settled  -  Mar 7, 2007
CNNMoney.comThese biotechs produce a similar drug called Increlex. The agreement also settles Insmed's lawsuit against Tercica, for allegedly marketing Increlex as

Tercica Settlement Forces Insmed to Find Alternatives for Drug  -  Mar 6, 2007
BloombergMarch 7 (Bloomberg) -- Tercica Inc.'s Increlex will soon be the only drug available to stimulate growth in abnormally short children,

Insmed, Tercica Settle Patent Suit Over Growth-Drug (Update3)  -  Mar 6, 2007
BloombergInsmed spokeswoman Jody LoMenzo declined to comment on potential reactions from patients taking Iplex and doctors who prefer it to Increlex.

To Settle Suit, Maker Agrees to Withdraw Growth Drug  -  Mar 6, 2007
New York Times,To protect its sales, Insmed had argued that its drug, Iplex, was superior to Tercica’s drug, Increlex, because it required only one injection a day instead

Insmed, Tercica Settle Genentech Growth-Drug Suit (Update2)  -  Mar 6, 2007
BloombergBoth Iplex and Increlex are given to children whose growth is stunted by the lack of a protein called insulin-like growth factor, which is created in the

Tercica "outperform," estimates raised  -  Mar 9, 2007
newratings.comTercica’s revenues from the Increlex drug were significantly ahead of the estimates, the analysts say. Tercica’s settlement with INSM has provided monopoly

Tercica 4Q loss widens on costs  -  Mar 8, 2007
BusinessWeekAssuming Tercica receives an approximate $17.8 million European-approval milestone payment for Increlex and issues to Ipsen a $15 million note for cash in

Market Report -- Short Stories (TRCA)  -  Mar 8, 2007
MSN MoneyThe firm says at most, IPLEX's absence, near-term, adds $1-2 mln in annual sales to Increlex's $2-3 mln current run rate. They say the current market

Tercica forces Insmed to scramble  -  Mar 8, 2007
Inside Bay Area,Tercica Inc.'s Increlex will soon be the only drug available to stimulate growth in abnormally short children, because of a settlement the company reached

Tercica, Genentech Settle Drug Patent Dispute  -  Mar 8, 2007
CBS 5,...comes three months after a federal jury in Oakland ruled Insmed violated patents owned by Genentech and licensed to Tercica for the drug Increlex.

Silicon Valley movers  -  Mar 8, 2007
San Jose Mercury News,The Brisbane company's Increlex soon will be the only drug available to stimulate growth in abnormally short children because of a settlement that blocks

Settlement means layoffs at Insmed  -  Mar 7, 2007
Richmond Times Dispatch,Tercica's drug, Increlex, is used to treat the same condition and began selling around the same time. Under licensing rights from Tercica, Insmed is still

Tercica hires first COO  -  Feb 28, 2007
San Francisco Business Times,Tercica lost $13.1 million in the quarter ended September, on sales of $316000 from its product Increlex, an injected drug for children who are very short

Ipsen's Full Year 2006 Results  -  Mar 18, 2007
American Digital Networks (press release),The first, Increlex(R), now represents as we anticipated the reference treatment for children suffering from severe primary IGF-1deficiency.

Biotech Day in Review: Avalon Signs $200 Million Deal with Merck  -  Mar 8, 2007
Seeking Alpha,Insmed will withdraw Iplex from the US market and also pull its approval application from European authorities, leaving the field open to Increlex,

Litigation Settlement Reached Between Tercica, Genentech and Insmed  -  Mar 7, 2007
PharmaLive.com (press release),Tercica (along with Ipsen, for Ipsen's Increlex territory) and Genentech will have the right to opt into Insmed's development and commercialization of each

Litigation Settlement Reached Between Tercica, Genentech and Insmed  -  Mar 6, 2007
Business Wire (press release),Tercica (along with Ipsen, for Ipsen’s Increlex territory) and Genentech will have the right to opt into Insmed’s development and commercialization of each

Ipsen s Full Year 2006 Results (12º)  -  Mar 18, 2007
InfoBolsa,...mainly related to payments due within the framework of alliances, such as Acapodene(R) and Increlex(TM), and to acquisition of software, against EUR 7.9

Hot Stocks of the Week: New Century Down  -  Mar 9, 2007
Forbes,Tercica makes Increlex, a growth hormone deficiency treatment. Tercica and its partner, Genentech Inc., sued a Glen Allen, Va.-based drug maker, Insmed Inc.

Tercica and Genentech Settle Infringement Suit Against Insmed  -  Mar 8, 2007
Patent Baristas,Tercica exclusively licensed these patents in April 2002 for use in its manufacture and sale of, among other things, Increlex. Prior to the trial,

Hearing Postponed in Patent Dispute by Makers of Biologics Iplex ...  -  Feb 17, 2007
Biologic Drug Report,Tercica, a California biopharmaceutical company that a year ago launched Increlex (mecasermin), is trying to get the judge to issue an injuction banning

Growth Drug Is Caught Up in Patent Fight  -  Feb 16, 2007
New York Times,But all new patients since then, they say, could be adequately treated with Tercica’s own drug, Increlex. The companies argue that Insmed’s patent

Afternoon Movers: Insmed, Beacon Power, Forgent Networks  -  Jan 9, 2007
Ant & SonsIn December, a jury found that Insmed infringed on patents used in its Increlex drug, and ordered damages of $7.5 million plus 15 percent of royalties in

Insmed Loses Patent Case to Tercica; Companies Should Merge  -  26 Dec 2006
Seeking Alpha,Tercica's drug, Increlex, is given twice a day by injection and Iplex, Insmed's drug, is given once a day. Iplex is cleverly delivered with a complementary

Jury Finds Insmed Infringed Genentech, Tercica Patents  -  26 Dec 2006
Genetic Engineering News (press release),Tercica exclusively licensed these patents from Genentech in April 2002 for use in its manufacture and sale of, among other things, Increlex™.

Stocks Turning In A Lackluster Performance - US Commentary  -  26 Dec 2006
Trading Markets,The loss by Insmed comes after a jury ruled that the company has infringed on patents used in Tercica's (TRCA | charts | news | PowerRating) Increlex drug,

Insmed Infringed Patents Owned by Genentech and Exclusively ...  -  26 Dec 2006
ag-IP-news Agency,...release by the company, Tercica exclusively licensed these patents in April 2002 for use in its manufacture and sale of, among other things, Increlex.

Jury rules against Insmed  -  26 Dec 2006
Richmond Times Dispatch,However, Tercica's Increlex and Insmed's iPlex have potential in far more common endocrine and metabolic conditions -- indications that also carry larger

Tercica Claims Victory in Patent Lawsuit  -  Dec 6, 2006
Houston Chronicle,Biopharmaceutical company Tercica Inc. said late Wednesday a jury found that rival Insmed Inc. infringed on patents used in its Increlex drug,

Genentech wins patent judgment  -  Dec 7, 2006
The Argus,Insmed's Iplex and Tercica's product, called Increlex, are growth drugs used to treat about 6000 short children who don't respond to normal human growth

Jury sides with Tercica in patent fight  -  Dec 6, 2006
San Francisco Business Times,Increlex is a recombinant form of the hormone insulin growth factor-1 or IGF-1. Richmond, Va.-based Insmed's (NASDAQ: INSM) Iplex is IGF-1 combined with a

Genentech, Tercica win damages in patent suit  -  Dec 7, 2006
Los Angeles Times,Richmond, Va.-based Insmed's Iplex and Tercica's product, called Increlex, are growth drugs used to treat about 6000 short children.

Jury Finds Insmed Infringed Patents Owned By Genentech And ...  -  Dec 7, 2006
PharmaLive.com (press release),Tercica exclusively licensed these patents in April 2002 for use in its manufacture and sale of, among other things, Increlex(TM). Prior to the trial,

Aftermarket Movers: Delia's Delights  -  Dec 6, 2006
Houston Chronicle,The case involved patents for a pediatric growth hormone treatment that Genentech Inc. sold to Tercicia for the drug Increlex.

Markets May Be Range-bound Ahead Of Friday's Payroll Numbers ...  -  Dec 7, 2006
Trading Markets,...its announcement that a jury has ruled that its rival Insmed (INSM | charts | news | PowerRating) has infringed on patents used in its Increlex drug.

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional